arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

GLAUKOS Corp

GKOS
$179.91 ▲ +8.97 (+5.25%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
52 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

GLAUKOS Corp faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $10.6B
Dividend Yield
Revenue Growth 49.5%
Op. Margin -9.3%
ROIC -2.6%
FCF / Share $0.21
Trailing P/E
Price / Book 15.5x
FCF Yield 0.1%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

52-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$185.61M
↑ +49.5%
Net Income Profit after all expenses
$-18.38M
↑ +6.5%
Operating Margin Operating profit as % of sales
-9.3%
↑ +29.5% 6th
FCF / Share Free cash flow per share
$0.21
↑ +172.3%
Long-Term Debt Long-term obligations
$3.04M
↓ -42.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
10
Returns
24
Financial Health
18
Cash Quality
26

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 14 years · 52 quarters